Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$9.69 +2.8%	$8.81	$5.00 ▼ $16.85	$567.16M	1.48	1.48 million shs	555,409 shs
ENTA Enanta Pharmaceuticals	$6.94 +5.3%	$6.73	$4.09 ▼ $16.73	$148.38M	0.84	279,221 shs	33,423 shs
KROS Keros Therapeutics	$14.30 +0.3%	$13.97	$9.12 ▼ $72.37	$580.91M	1.26	862,379 shs	42,900 shs
TYRA Tyra Biosciences	$10.76 +6.2%	$9.83	$6.42 ▼ $29.60	$571.04M	1.07	290,127 shs	36,968 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	-4.92%	-15.61%	+5.45%	+16.37%	-29.51%
ENTA Enanta Pharmaceuticals	-5.32%	-14.97%	-12.13%	+33.67%	-60.16%
KROS Keros Therapeutics	-2.20%	+2.44%	+5.09%	+5.32%	-72.08%
TYRA Tyra Biosciences	-7.15%	+2.22%	-2.88%	+17.65%	-49.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNA Ginkgo Bioworks	0.7366 of 5 stars	1.0	1.0	0.0	2.1	2.5	1.3
ENTA Enanta Pharmaceuticals	3.9191 of 5 stars	3.4	1.0	4.7	3.1	2.5	0.0
KROS Keros Therapeutics	2.0754 of 5 stars	3.3	1.0	0.0	2.7	3.3	0.0
TYRA Tyra Biosciences	3.1016 of 5 stars	3.5	5.0	0.0	1.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNA Ginkgo Bioworks	2.00	Hold	$8.50	-12.28% Downside
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	159.37% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.56	113.75% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	186.53% Upside

Current Analyst Ratings Breakdown

Latest ENTA, KROS, DNA, and TYRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00
5/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $25.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNA Ginkgo Bioworks	$227.04M	2.50	N/A	N/A	$13.17 per share	0.74
ENTA Enanta Pharmaceuticals	$67.64M	2.19	N/A	N/A	$6.08 per share	1.14
KROS Keros Therapeutics	$3.55M	163.57	N/A	N/A	$14.11 per share	1.01
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNA Ginkgo Bioworks	-$547.03M	-$9.16	N/A	N/A	N/A	-198.84%	-52.35%	-27.14%	8/14/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
KROS Keros Therapeutics	-$187.35M	-$0.18	N/A	N/A	N/A	1.96%	0.75%	0.69%	8/6/2025 (Estimated)
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	8/6/2025 (Estimated)

Latest ENTA, KROS, DNA, and TYRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	KROS Keros Therapeutics	-$1.13	N/A	N/A	N/A	$3.83 million	N/A
8/6/2025	Q2 2025	TYRA Tyra Biosciences	-$0.53	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.10	N/A	N/A	N/A	$16.21 million	N/A
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNA Ginkgo Bioworks	N/A	4.88	4.88
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
KROS Keros Therapeutics	N/A	19.29	19.29
TYRA Tyra Biosciences	N/A	22.78	22.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNA Ginkgo Bioworks	78.63%
ENTA Enanta Pharmaceuticals	94.99%
KROS Keros Therapeutics	71.56%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
DNA Ginkgo Bioworks	9.72%
ENTA Enanta Pharmaceuticals	13.89%
KROS Keros Therapeutics	22.90%
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNA Ginkgo Bioworks	640	58.53 million	52.84 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
KROS Keros Therapeutics	100	40.62 million	31.31 million	Optionable
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable

ENTA, KROS, DNA, and TYRA Headlines

Recent News About These Companies

Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.9% - What's Next?

July 15 at 2:10 PM | marketbeat.com

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Morningstar

July 9, 2025 | morningstar.comM

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

July 8, 2025 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 3.3% - What's Next?

July 3, 2025 | marketbeat.com

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

July 2, 2025 | targetedonc.comT

Tyra Biosciences begins patient dosing in phase 2 study of TYRA-300 in low-grade intermediate risk non-muscle invasive bladder cancer

July 1, 2025 | pharmabiz.comP

Tyra Biosciences' (TYRA) "Buy" Rating Reiterated at HC Wainwright

July 1, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Rating of "Buy" by Brokerages

July 1, 2025 | marketbeat.com

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

June 30, 2025 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 5.6% - Here's What Happened

June 23, 2025 | marketbeat.com

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 9,568 Shares of Stock

June 21, 2025 | insidertrades.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $93,575.04 in Stock

June 20, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in Stock

June 17, 2025 | insidertrades.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan Sells 6,814 Shares

June 16, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $154,650.00 in Stock

June 16, 2025 | marketbeat.com

Gilla Kaplan Sells 30,000 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

June 16, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 3% - What's Next?

June 16, 2025 | marketbeat.com

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025 | prnewswire.com

One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

May 9, 2025 | finance.yahoo.com

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
Super Micro Computer Stock's Rally Backed by Strong Financials
By Gabriel Osorio-Mazilli | June 19, 2025
View Super Micro Computer Stock's Rally Backed by Strong Financials
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks
Snag These 3 Bargain Tech Stocks Before They Pop
By Gabriel Osorio-Mazilli | June 27, 2025
View Snag These 3 Bargain Tech Stocks Before They Pop

ENTA, KROS, DNA, and TYRA Company Descriptions

Ginkgo Bioworks NYSE:DNA

$9.69 +0.26 (+2.76%)

As of 10:49 AM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Enanta Pharmaceuticals NASDAQ:ENTA

$6.94 +0.35 (+5.31%)

As of 10:49 AM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Keros Therapeutics NASDAQ:KROS

$14.30 +0.05 (+0.32%)

As of 10:49 AM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Tyra Biosciences NASDAQ:TYRA

$10.76 +0.63 (+6.23%)

As of 10:49 AM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time